Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
Clarke, N; Ali, A; Ingleby, F
; Hoyle, A; Amos, C; Attard, G; Brawley, C; Calvert, J; Chowdhury, S; Cook, A; +41 more...Cross, W; Dearnaley, D; Douis, H; Gilbert, D; Gillessen, S; Jones, R; Langley, R; MacNair, A; Malik, Z; Mason, M; Matheson, D; Millman, R; Parker, C; Ritchie, A; Rush, H; Russell, J; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, J; Parikh, O; Protheroe, A; Rudman, S; Srihari, N; Simms, M; Tanguay, J; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, M; Parmar, M; James, N; STAMPEDE investigators and
(2020)
Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003.
ANNALS OF ONCOLOGY, 31 (3).
442-.
ISSN 0923-7534
DOI: 10.1016/j.annonc.2020.01.002
The authors regret that Fig.2F has been incorrectly titled. The correct title is “Failure-free survival high burden M1”.
Item Type | Article |
---|---|
Elements ID | 144961 |
Date Deposited | 15 Jan 2021 14:50 |
ORCID: https://orcid.org/0000-0003-1800-2015